Archive - Latest News Search Engine - Global and Local Breaking News

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device

Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device

AbbVie to Host Second-Quarter 2025 Earnings Conference Call

AbbVie to Host Second-Quarter 2025 Earnings Conference Call

Your briefing

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

-TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data exp...

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

TOKYO, June 30, 2025 /PRNewswire/ -- Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnersh...

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device

Co-financing by the EIC Fund to ramp up women's health solution to POP MISGAV, Israel, June 30, 2025 /PRNewswire/ -- Escala Medical Ltd. ("Escala"), a...

Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device

AbbVie to Host Second-Quarter 2025 Earnings Conference Call

NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2...

AbbVie to Host Second-Quarter 2025 Earnings Conference Call